Jillian Rosengard, MD
Clinical Neurophysiology · Bronx, NYNPI 1528320397
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 30 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by UCB, Inc. at 35.8% of the total. That places this record below the midpoint for clinical neurophysiology clinicians in NY, where the typical reported total is $1,360.
Across 30 payments — averaging $40.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$438
- SK Life Science, Inc.$260
- Neuropace, Inc.$150
- Greenwich Biosciences, Inc.$119
- Adamas Pharmaceuticals, Inc.$69
- Jazz Pharmaceuticals Inc.$67
- plus $117 from 3 others
What the payments were for
- Speaking & faculty fees$232%
- Food & beverage$1,19898%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 10 | $438 |
| SK Life Science, Inc. | 2 | $260 |
| Neuropace, Inc. | 1 | $150 |
| Greenwich Biosciences, Inc. | 4 | $119 |
| Adamas Pharmaceuticals, Inc. | 3 | $69 |
| Jazz Pharmaceuticals Inc. | 4 | $67 |
| Aquestive Therapeutics, Inc. | 3 | $51 |
| Sunovion Pharmaceuticals Inc. | 2 | $43 |
| Acorda Therapeutics, Inc | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,221 in reported general payments places this provider in the 45th percentile of 35 clinical neurophysiology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpidiolexCannabidiol (Cbd) | 23 | $135,510 |
| XcopriCenobamate | 37 | $59,979 |
| BanzelRufinamide | 19 | $53,814 |
| BriviactBrivaracetam | 15 | $30,104 |
| Trokendi XrTopiramate | 11 | $25,150 |
| Rufinamide | 28 | $23,183 |
| Lacosamide | 169 | $19,857 |
| VimpatLacosamide | 20 | $17,874 |
| QuliptaAtogepant | 13 | $13,875 |
| Nurtec OdtRimegepant Sulfate | 13 | $13,203 |
| Oxcarbazepine | 81 | $8,177 |
| Levetiracetam | 272 | $6,590 |
| Clobazam | 38 | $5,341 |
| Carbamazepine ErCarbamazepine | 49 | $4,583 |
| Divalproex Sodium ErDivalproex Sodium | 35 | $4,156 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| SK Life Science, Inc.Xcopri | $260 | $59,97937 claims |
| UCB, Inc.Briviact, Vimpat | $438 | $47,97835 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 35 clinical neurophysiology providers in New York.
Other clinical neurophysiology in Bronx
- Farhad Kadkhodaei ElyaderaniBronx$156K
- Jonathan GurskyBronx$1K
- Swetha PedavallyBronx$778
- Orly WillsBronx$258
- Alcibiades RodriguezNew York$714K
- Jessica Robinson-PappNew York$28K
- Mohini GurmeWest Nyack$13K
- Cecily AntoHauppauge$11K
- Itzhak HaimovicGreat Neck$7K
- Madeline FieldsNew York$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.